Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan-Dec;65(1):e12588.
doi: 10.1111/cga.12588.

A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

Mariko Honma  1 , Naoto Suzuki  1 , Mikako Goto  2 , Taku Obara  3   4   5 , Yoshiyuki Saito  6 , Ken Nakajima  7 , Ritsuko Yamane  8 , Kunihiko Takahashi  9 , Takeo Nakayama  6 , Masahiro Hayashi  8 , Atsuko Murashima  2 , Akira Toyama  1
Affiliations

A case series study on the safety of cefditoren pivoxil use during the first trimester of pregnancy in Japan

Mariko Honma et al. Congenit Anom (Kyoto). 2025 Jan-Dec.

Abstract

We evaluated the teratogenic risk associated with exposure to cefditoren pivoxil during the first trimester of pregnancy using the integrated databases of the Toranomon Hospital and the National Center for Child Health and Development. Among 13 599 registered individuals, the analysis included 285 subjects who had taken cefditoren pivoxil during the first trimester of pregnancy. The rates of stillbirth, miscarriage, and elective terminations were 0.4%, 5.6%, and 2.1%, respectively. Among 262 live births, the rates of preterm birth, low birth weight, and major congenital malformations were 4.6%, 5.7%, and 1.2%, respectively. Our results suggest that exposure to cefditoren pivoxil during the first trimester of pregnancy does not significantly increase the risk of adverse pregnancy outcomes and infant outcomes.

Keywords: cefditoren pivoxil; database; major congenital malformation; pregnancy; safety.

PubMed Disclaimer

References

REFERENCES

    1. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population‐based, case‐control study. Am J Obstet Gynecol. 2001;184:1289‐1296.
    1. Suzuki H, Kawano J, Sakai T, et al. Cefditoren pivoxil administered to pregnant women. Jpn J Chemother. 2001;49:331‐339. (in Japanese).
    1. Hishinuma K, Yamane R, Yokoo I, et al. Pregnancy outcome after first trimester exposure to domperidone—an observational cohort study. J Obstet Gynaecol Res. 2021;47:1704‐1710.
    1. Yamaguchi Y, Yamada T, Goto M, et al. Analysis of triptan use during pregnancy in Japan: a case series. Congenit Anom (Kyoto). 2022;62:78‐81.
    1. Hatakeyama S, Goto M, Yamamoto A, et al. The safety of pranlukast and montelukast during the first trimester of pregnancy: a prospective, two‐centered cohort study in Japan. Congenit Anom (Kyoto). 2022;62:161‐168.

LinkOut - more resources